Genomic Profiling Assay in Phase I

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-07-13

Study Completion Date

2021-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this research study is to collect and test tumor tissue from patients with advanced cancers that may be enrolled in Phase 1 studies or other treatments. Researchers will study if the results from genetic testing can help researchers determine which therapy may prove more beneficial for a patient in the future.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

NCT01772771

Glioma Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm +2 more

RECRUITING

Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions

NCT01457196

Neoplasm

COMPLETED NA

Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

NCT00897117

Lung Cancer

RECRUITING

Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics

NCT03027401

Neoplasms Adenomatous Polyposis Coli Neurofibroma, Plexiform +1 more

WITHDRAWN

Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression

NCT01433224

Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor Ovarian Cancer +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

If you agree to take part in this study, your tumor tissue collected previously from surgery or a prior biopsy (archived tissue) will be used for genetic testing. Genetic testing looks at whether specific genes are changed (mutated) in the tumor.

The results of the genetic testing will be documented in your medical record. Your doctor may use the results of the genetic testing to help decide which treatment you will have. While awaiting results of the genomic profile assay, you may be enrolled in another treatment either at MD Anderson or near your home. This will be decided by your treating physician.

Your samples will be given a code number when they are sent for genetic testing to Foundation Medicine. No identifying information will be directly linked to your samples. Only the researcher in charge of sending all tissue for testing will have access to the code numbers and be able to link the samples to you. This is to allow medical data related to the samples to be updated as needed. Foundation Medicine will not be able to link this data to you.

Researchers will also review your medical history from before and following the collection of tissue, to learn if the use of genetic testing had any effect on the outcome of your treatment.

This is an investigational study.

Up to 300 participants will take part in this study. All will be enrolled at MD Anderson.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group #1

Participants who have had tumor molecular analysis performed with the similar clinical characteristics and genomic aberrations but who receive therapy not matched to their aberrations, or who have received results from Foundation Medicine that fail to demonstrate any molecular alteration.

Tumor Tissue

Intervention Type PROCEDURE

Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.

Control Group #2

Participants from historical archives of MD Anderson, no older than two years, who received therapy not matched to their aberrations and are matched not only on the basis of the clinical characteristics, but also, as much as possible, on the basis of genomic aberrations.

Tumor Tissue

Intervention Type PROCEDURE

Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.

Matched Targeted Therapy Group

Participants with tumor aberrations who received matched targeted therapy.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tumor Tissue

Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with advanced cancer.
2. Consent for use of archival tissue from primary or metastatic cancer diagnosis. Note: Patients may currently be enrolled in other investigational protocol including treatment protocols.
3. Control Group #2 only: Control Group #2 will consist of 100 patients from MDACC/Phase I historical archives. Patients (cases no older than 2 years) will be selected based on clinical characteristics and genomic alterations similar to matched targeted therapy group.
4. Patients may have received prior 'matched' therapies; however, at the time of enrollment, patients may not currently be on a known 'matched' therapy, and may not have received a 'matched' therapy as the last treatment if not receiving treatment at the time of consent.
5. Patients who have a life expectancy of greater than 3 months.

Exclusion Criteria

1. Patients with advanced cancer who are NOT likely to meet the additional enrollment criteria in matched targeted therapy protocols or treatments.
2. Patients who do not have archival tissue available.
3. Patients are excluded if their last treatment before enrollment included a targeted agent matched to a genomic alteration in the patient's tumor.

Eligible Sex

ALL

Accepts Healthy Volunteers

No